Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7637660 | 0.82 | CA2 (0.54) | PIK3CDPIK3CGPIK3CBMAPTCA1 | |
| SCHEMBL7211610 | 0.81 | CA2 (0.39) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL7212785 | 0.79 | PTGS2 (0.47) | PIK3CDPIK3CGPIK3CBTP53POLB | |
| SCHEMBL6151457 | 0.79 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CBPTGS2PTGS1 | |
| SCHEMBL7211481 | 0.76 | PTGS2 (0.49) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL1068744 | 0.76 | PTGS1 (0.62) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL7212753 | 0.75 | EDNRA (0.57) | TP53POLBMAPTKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL16015053 | 0.75 | PTGS1 (0.60) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL6721488 | 0.71 | PTGS1 (0.56) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL1068740 | 0.71 | CA12 (0.50) | CA1CA2PTGS2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613804-B2 | Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock | ENCYSIVE PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRB, EDNRA, ECE2 | PIK3CD 3918/4885PIK3CG 3883/4885PIK3CB 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.